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Abstract
Modifications occurring on autoantigens during cell death have
been proposed to have a role in the initiation of autoimmune
diseases. Patients suffering from mixed connective tissue
disease (MCTD) produce autoantibodies directed to U1 small
nuclear ribonucleoprotein (snRNP), and antibodies against a 70
kDa protein component, the U1-70K (70K) protein, are the most
prominent. During apoptosis, 70K is cleaved by caspase-3 to a
40 kDa product, which remains associated with the complex.
Autoantibodies preferentially recognizing the apoptotic form of
70K have been described previously, and an apoptosis-specific
epitope on 70K has been identified. This study shows that 29 of
53 (54%) MCTD sera preferentially recognize the apoptotic
form of 70K over intact 70K. Moreover, we show that antibodies
directed to an apoptosis-specific epitope on 70K are more
specifically associated with MCTD than other anti-70K
antibodies, suggesting that apoptotic 70K is a better antigen for
the detection of these antibodies in MCTD patients.
Longitudinal analysis of 12 MCTD patients showed in several
patients that early sera are relatively enriched with antibodies
recognizing an apoptosis-specific epitope, and that the levels of
these apoptosis-specific antibodies decrease in time. These
findings indicate that the early detection of apoptotic 70K is of
considerable interest for anti-U1 snRNP-positive patients.
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Introduction
Patients suffering from autoimmune diseases are charac-
terized by the presence of autoantibodies directed to a
wide range of autoantigens. Mixed connective tissue dis-
ease (MCTD) is a relatively rare systemic autoimmune dis-
ease and includes a group of patients with overlapping
clinical symptoms of systemic lupus erythematosus (SLE),
systemic sclerosis (SSc), rheumatoid arthritis and polymy-
ositis/dermatomyositis. Sharp and colleagues were the first
to describe MCTD as a distinct rheumatic disease [1], but
whether MCTD can be regarded as a distinct disorder has
been a subject of discussion [2]. A characteristic serologi-
cal feature that distinguishes MCTD patients from patients
with other connective tissue diseases is high levels of
autoantibodies directed against the U1 small nuclear ribo-
nucleoprotein (snRNP) particle [1,3]. The U1 snRNP is a
highly conserved RNA–protein complex, located in the
nucleus, where it is involved in the processing of pre-mRNA
[4,5]. It consists of the U1 snRNA molecule and several
proteins: the U1A, U1C and U1-70K (70K) proteins are
components specific for the U1 snRNP, whereas the seven
Sm proteins (B/B', D1, D2, D3, E, F and G) are shared with
other U snRNPs [6]. Most U1 snRNP components are
autoantigenic in MCTD and SLE. Autoantibodies directed
against U1A, U1C, 70K and the U1 snRNA molecule are
mainly found in MCTD patients, whereas autoantibodies
targeting Sm-D, Sm-B/B' and the E.F.G complex are more
specifically associated with SLE [7,8].
70K = U1-70K; 70Kapop = apoptotic cleavage product of U1-70K protein of about 40 kDa; MCTD = mixed connective tissue disease; NP40 = Nonidet 
P40; RNP = ribonucleoprotein; SLE = systemic lupus erythematosus; snRNP = small nuclear ribonucleoprotein; SSc = systemic sclerosis; U1-70K 
= 70 kDa protein component of the U1 snRNP complex.
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The mechanisms through which such autoantigens, gener-
ally highly conserved and ubiquitously expressed mole-
cules, escape tolerance and are recognized by the immune
system as non-self remain unclear, but it is proposed that
cell death is important in the initiation of autoimmune
responses [9,10]. Recently, secondary necrosis has also
been put forward as a source of proteolytically modified
autoantigens [11], but the modifications that occur on
autoantigens during apoptosis were studied most exten-
sively. Apoptotic modifications on autoantigens include
specific cleavage by caspases or granzyme B,
(hyper)phosphorylation, dephosphorylation, citrullination,
methylation and transglutaminase cross-linking [10,12,13],
and it is thought that these modifications might be seen by
the immune system as novel 'cryptic' epitopes. It is believed
that these novel epitopes induce the primary immune
response, and that secondary immune responses and
epitope spreading result in autoantibodies that are directed
against unmodified regions of the autoantigens and anti-
gens that are associated with the initially modified autoan-
tigen [9].
One of the apoptotic modifications occurring on the U1
snRNP is the cleavage of 70K at residue 341 by caspase-
3 [14,15]. Antibodies against 70K are in general the first
autoantibodies to appear in anti-U1 snRNP (often referred
to as anti-RNP) positive patients, indicating that 70K is
important as an initial autoantigen [16]. The molecular and
immunological characteristics of the major apoptotic iso-
form of 70K, a 40 kDa cleavage product that remains asso-
ciated with the U1 snRNP complex [17], and its role in the
triggering of the primary and possibly secondary autoim-
mune response, are therefore intriguing.
Recently it was shown that sera of some anti-U1 snRNP
positive patients contain antibodies that specifically bind to
the apoptotic form of 70K, which displays an epitope that
is not present on the intact form [18,19]. This epitope is
dependent on the region between amino acids 180 and
205, partly overlapping with the RNA-binding domain and
overlapping with the most common T cell epitope [20]. In
this study we analyzed a cohort of MCTD and control
patients for the presence of autoantibodies against intact
and apoptotic 70K. Moreover, we longitudinally analyzed
sera from another group of MCTD patients. Our results
show that, early in disease, autoantibodies directed against
the apoptotic form of 70K (70Kapop) are more strongly rep-
resented than autoantibodies against the intact form. Lon-
gitudinal studies also show that autoantibodies against
70Kapop are not significantly correlated with disease flares.
Methods
Patient sera
All patients were seen at the Department of Rheumatology
of the University Medical Centre Nijmegen or the St
Maartenskliniek Nijmegen (The Netherlands), and were
classified in accordance with standard criteria for each dis-
ease. All MCTD patients (n = 53) tested positive for anti-
U1 snRNP autoantibodies by counter-immunoelectro-
phoresis, and for antibodies against one or more compo-
nents of the U1 snRNP complex by immunoblotting. Most
of the sera (91%) were also RNP positive as shown by U1
snRNA co-immunoprecipitation. Longitudinal serum collec-
tions were obtained from 12 MCTD patients and have been
described previously [21]. From each patient, over a period
of 4–15 years (average 10 years), 8 to 33 serum samples
(average 18 samples) were available and were analyzed.
During the follow-up study, the patients were regularly mon-
itored for clinical and serological parameters. At each visit
the disease activity was measured in accordance with a val-
idated SLE disease activity index described by Ter Borg
and colleagues [22]. Medication was given as indicated by
the clinical status. Additionally, patient sera were collected
from SLE (n = 48), polymyositis/dermatomyositis (n = 26),
primary Sjögren's syndrome (n = 18), SSc (n = 10), rheu-
matoid arthritis (n = 3), Raynaud's phenomenon (n = 3) and
undefined connective tissue disease (n = 1). Informed con-
sent was obtained from all participants in accordance with
the medical ethical regulations of the local ethics commit-
tee. Sera were stored at -70°C until use.
Cell lines, induction of cell death and preparation of cell 
extracts
Jurkat (human T cell leukemia) suspension cells were
grown in RPMI 1640 medium (Gibco-BRL), supplemented
with 1 mM sodium pyruvate, 1 mM penicillin, 1 mM strepto-
mycin and 10% heat-inactivated fetal calf serum (Gibco-
BRL), in a humidified 37°C incubator containing 5% CO2.
Cells were maintained at a concentration of 106 cells/ml
and were induced to undergo apoptosis by the addition of
10 µg/ml anisomycin. Eight hours after induction, apoptotic
cells were harvested by centrifugation at 800 g for 10 min
and washed with PBS. Apoptotic and non-apoptotic Jurkat
cells were resuspended in Nonidet P40 (NP40)-containing
lysis buffer (25 mM Tris-HCl, pH 7.6, 100 mM KCl, 10 mM
MgCl2, 0.25 mM dithioerythritol, 1% NP40, Complete™
protease inhibitor cocktail [Roche]) at a concentration of
108 cells/ml. Cells were lysed on ice for 30 min and subse-
quently centrifuged for 30 min at 12,000 g and 4°C. Super-
natants were used immediately or stored at -70°C.
SDS–polyacrylamide gel electrophoresis and western 
blotting
Cell extracts of 1.3 × 107 non-apoptotic Jurkat cells and 1.3
× 107 apoptotic Jurkat cells, either separately or mixed,
were separated by SDS–polyacrylamide gel electrophore-
sis. Directly after gel electrophoresis, proteins were trans-
ferred to a nitrocellulose membrane (Schleicher & Schuell)
by semi-dry electroblotting. Staining of the membrane with
Ponceau S (Sigma) was used to verify protein transfer.
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Probing western blots with patient sera
All incubation steps were performed at approximately 20°C
on a shaking table. Western blots containing non-apoptotic
and apoptotic Jurkat cell extracts were pre-blocked with
5% non-fat dried milk in PBS containing 0.1% NP40
(MPBS/NP40) for 2 hours. Subsequently, membranes
were incubated with patient serum, diluted 1000–5000-
fold in MPBS/NP40, for 1 hour. After extensive washing
with PBS containing 0.1% NP40 (PBS/NP40), mem-
branes were incubated with horseradish peroxidase-
labeled rabbit anti-human IgA/IgG/IgM antibody (Dako
Immunoglobulins), diluted 1000-fold in MPBS/NP40, for 1
hour. After several washes with PBS/NP40 and PBS,
bound antibodies were detected by enhanced chemilumi-
nescence. Antibody reactivities against 70K and 70Kapop
were scored ranging from 0 to 5 by three researchers inde-
pendently. In each experiment several control antibodies
were used.
Results
In this study, patient sera were analyzed for the presence of
autoantibodies against 70K and its apoptotic product
(70Kapop), on western blots containing extracts of non-
apoptotic and apoptotic Jurkat cells. Two positive controls
for the detection of 70K and 70Kapop were included in each
experiment: anti-70K mouse monoclonal antibody 2.73
[23], which displays higher reactivities with 70K than with
70Kapop, and serum from MCTD patient B16, which reacts
with both 70K and 70Kapop. The position of 70Kapop on
western blots was confirmed by a recombinant monoclonal
antibody recognizing both 70K and 70Kapop (Fig. 1a) [24].
The results show that in these apoptotic cells 70K is con-
verted almost completely into 70Kapop. Besides positive
controls for 70K and 70Kapop, mouse monoclonal antibody
ANA125 directed against Sm-B/B' (Fig 1a), and anti-U1-A/
U2-B" mouse monoclonal antibody 9A9 (not shown) were
also used. To be able to detect autoantibody reactivities to
the intact 70K and its apoptotic 40K fragment simultane-
ously and to facilitate a direct comparison of these reactiv-
ities, a mixture of apoptotic and non-apoptotic cell extracts
was used to prepare western blots. An additional advan-
tage of this approach was that differences between blots
could be excluded, thereby allowing a more accurate com-
parison of reactivities with 70K and 70Kapop in a single
patient serum. Serum antibody reactivities against 70K and
70Kapop were scored ranging from 0 to 5. Figure 1b shows
a western blot containing such a mixture of non-apoptotic
and apoptotic Jurkat cell extracts, probed with a serial dilu-
tion of serum from MCTD patient B16. It can be seen that
the signals for 70K and 70Kapop increase when the serum
is applied at a lower dilution, indicating that the western
blot assay can be used for semi-quantitative interpretation.
Autoantibodies against 70K are more easily detected 
with 70Kapop
The presence of high levels of autoantibodies directed
against components of the U1 snRNP, such as 70K, is one
of the criteria for the diagnosis of MCTD [2]. However, anti-
70K antibodies are also found in some SLE and SSc
patients [3]. To compare the disease specificity of anti-
70Kapop and anti-70K autoantibodies, sera from a group of
MCTD patients and from a group of patients suffering from
a variety of autoimmune disorders were analyzed. As shown
in Table 1, most MCTD patients (54%) displayed antibody
reactivities that preferentially recognized 70Kapop over the
intact 70K protein. Seven patients (13%) reacted with 70K
and 70Kapop with similar efficiencies, and only 6% of the
MCTD patients reacted preferentially with the intact 70K
protein. Fourteen sera (27%) did not react detectably with
either 70K polypeptide, although the sera were anti-RNP
positive by several techniques. These results indicate that
70Kapop is a better antigen than the intact 70K protein for
the detection of anti-70K autoantibodies. Antibody reactiv-
ity with 70Kapop was found in only 2% of sera from control
groups, whereas antibody reactivity with 70K was found in
5% of patient sera from control groups.
Autoantibodies against 70Kapop are not correlated with 
disease activity
It has been described that, in some patients with MCTD,
antibody titers against the U1 snRNA molecule are corre-
lated with disease activity, and could even possess prog-
nostic value [21]. In contrast, most studies did not find a
correlation between disease activity and antibody
responses to 70K, either by serum analysis using recom-
binant protein as antigen in ELISA [21,25] or by analysis on
western blots using native protein from cell extracts [26].
Only one study, using ELISA with recombinant 70K as
technique, has reported decreasing disease activity con-
comitant with decreasing anti-70K antibody levels [27].
Because apoptotic modifications on autoantigens, such as
the cleavage of 70K, are believed to be involved in the pri-
mary autoimmune response, we proposed that immune
complexes containing anti-70Kapop antibodies might also
be important for triggering disease flares. Serum samples
were collected longitudinally from 12 MCTD patients by a
follow-up during variable time intervals (4–15 years; aver-
age 10 years). All samples were analyzed for the presence
of autoantibodies against 70K and 70Kapop on western
blots containing non-apoptotic and apoptotic Jurkat cell
extracts, and the presence of these autoantibodies was
compared with the disease activity of each patient. The
overall conclusion of this longitudinal study was that no sig-
nificant correlations between antibody titres against either
70Kapop or 70K and disease exacerbations could be
observed.
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Figure 1
Anti-U1-70K and anti-70Kapop detection by western blotting. Apoptosis was induced in Jurkat cells by incubation with anisomycin for 8 hours. West-
ern blots were prepared with the resulting cell extracts, and the positions of relevant polypeptides were revealed with patient sera and monoclonal 
antibodies with the use of a chemiluminescent detection procedure. The positions of the various proteins are indicated on the left, and molecular 
mass marker positions on the right. (a) U1-70K (70K) detected with a serum from MCTD patient B16 (lanes 1 and 5), anti-70K monoclonal antibody 
2.73 (lanes 2 and 6) and an anti-70K single-chain recombinant antibody (scFv; lanes 3 and 7) (70K); lanes 4 and 8, Sm-B/B' detected with a mono-
clonal anti-Sm-B/B' antibody (ANA125); the position of U1A, which is also recognized by serum from MCTD patient B16 (lanes 1 and 5), was deter-
mined by a U1A-specific monoclonal antibody (not shown). In apoptotic cells (lanes 5–8), 70K is present as a 40 kDa species (70Kapop). (b) A 
serum sample from MCTD patient B16 was applied at 5000-fold (lane 1), 10,000-fold (lane 2) and 20,000-fold (lane 3) dilution on a western blot 
containing a mixture of non-apoptotic and apoptotic Jurkat cell extracts. In lane 4 the 70K protein was detected with mouse monoclonal antibody 
2.73, which reacts much more efficiently with 70K than with 70Kapop.
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Autoantibodies against 70Kapop are more prevalent early 
in disease
As mentioned above, it has been proposed that apoptotic
modifications trigger the primary immune response
towards self proteins and that, through secondary immune
responses and epitope spreading, autoantibodies directed
against unmodified regions on the autoantigen appear at
later stages of the disease. To investigate this possibility for
the 70K autoantigen, the longitudinal serum collection [21]
of 12 MCTD patients was re-examined, now for antibodies
against 70K and for antibodies against 70Kapop. Three
patients produced antibodies reacting strongly with
70Kapop, whereas no or only weak reactivity against 70K
was observed. In one of these three patients, autoantibod-
ies against 70Kapop were more prevalent in early serum
samples, and the level decreased in time. Eight patients
were found to have high titres of antibodies with reactivities
to both 70K and 70Kapop. Interestingly, in three of these
patients early serum samples showed a higher reactivity
with 70Kapop than with 70K, whereas later samples showed
comparable reactivities with both antigens, or higher reac-
tivities with 70K. An example of this type of reactivity profile
is shown in Fig. 2. One of the 12 patient sera did not
detectably contain antibodies directed against 70K or
70Kapop. These results thus support the idea that antibod-
ies against 70Kapop appear earlier in the disease than anti-
bodies against the complete 70K protein.
Discussion
Greidinger and colleagues recently showed that antibodies
against the 70K protein in RNP-positive patients are often
accompanied by antibodies directed against the apoptotic
cleavage product of this autoantigen and that the B cell
epitopes recognized on the apoptotic product are antigen-
ically different from those contained in the intact form of the
70K protein [18,19]. This study is the first to confirm and
extend these findings and strongly suggests that the reac-
tivity of a patient serum with anti-70K antibodies depends
on the presence of antibodies against epitopes shared by
70K and 70Kapop, and on the presence of antibodies
against epitopes exclusively present on 70Kapop. The major
apoptosis-specific epitope on 70K has been shown to be
located in the region containing the RNA-binding domain,
and its formation depends on amino acids 180–205, over-
lapping with the most common T cell epitope [20]. Other
apoptosis-specific epitopes on 70K have not yet been
described. In our recent studies, monoclonal recombinant
human antibodies against 70K were isolated from phage
display libraries derived from SLE patients, and several of
these monoclonal antibodies preferentially recognized
Table 1
Recognition of U1-70K (70K) and its apoptotic cleavage product (70Kapop) by patients with different autoimmune disorders
No. (%) of patients with disorder
Patient group (disease) No. of patients 70Kapop 70Kapop > 70K 70Kapop = 70K 70K > 70Kapop 70K
MCTD 53 15 (28) 14 (26) 7 (13) 1 (2) 2 (4)
SLE 48 0 1 (2) 1 (2) 0 1 (2)
Non-SLEa 61 0 0 0 0 2 (3)
aThe control group of non-systemic lupus erythematosus (non-SLE) patients consists of patients suffering from polymyositis/dermatomyositis (n = 
26), primary Sjögren's syndrome (n = 18), systemic sclerosis (n = 10), rheumatoid arthritis (n = 3), Raynaud's phenomenon (n = 3) and undefined 
connective tissue disease (n = 1). MCTD, mixed connective tissue disease.
Figure 2
Longitudinal anti-70K analysis of patient T2. Eighteen serum samples taken over a period of 7 years with approximately equal time intervals were 
analyzed on western blots containing non-apoptotic and apoptotic Jurkat cell extracts. The positions of U1-70K (70K), of which two isoforms are vis-
ible, and 70Kapop are indicated on the left. In lane 19, 70K was detected with mouse monoclonal 2.73, which reacts much more strongly with 70K 
than with 70Kapop. MoAb, monoclonal antibody.
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70Kapop on a western blot and in immunoprecipitation
experiments ([24], and D Hof, unpublished results). It is
believed that the apoptotic cleavage of 70K leads to the
exposure of a neo-epitope that, if presented to the immune
system, triggers the autoimmune response. Greidinger and
colleagues showed that a mutant consisting of the amino-
terminal 205 amino acids, was indeed able to induce an
anti-70Kapop antibody response in mice, with subsequent
epitope spreading. Interestingly, some of the immunized
mice developed pulmonary lesions comparable to lesions
found in lungs of MCTD patients. This finding supports the
hypothesis that apoptosis-specific epitopes, and antibod-
ies directed against them, might have a pathological role in
the triggering and maintenance of the human autoimmune
response to 70K [19].
In our study, a minority of MCTD sera (4%) contained
autoantibodies exclusively reacting with intact 70K. We
suggest that these sera derive from patients in a relatively
late disease phase and primarily contain antibodies result-
ing from expanded epitope spreading. Most epitopes rec-
ognized by these sera might therefore be dependent on the
carboxy-terminal part of the protein, which is cleaved off
during apoptosis and is not present on 70Kapop. Patients
that tested negative in our western blot experiments might
either have low levels of anti-70K antibodies or might not
produce such antibodies at all. Instead, other components
of the U1 snRNP, such as the U1 RNA molecule, U1A or
U1C, might be targeted by these sera and might explain
their anti-U1 snRNP reactivity.
We show here that most U1 snRNP-positive patient sera
preferentially recognize 70Kapop, which is most probably
explained by the presence of antibodies targeting an apop-
totic 70K epitope. These results are in line with reports by
Greidinger and colleagues [18,19], who found that about
50% of their RNP-positive sera contained 70Kapop autoan-
tibodies.
How disease flares are induced is not completely under-
stood. Correlations between serum levels of certain
autoantibodies and disease activity have been reported for
MCTD and SLE [21,22], but it can be disputed whether
these antibodies contribute to the disease flares or are
merely epiphenomena. Our data show that antibodies
against 70Kapop are not significantly correlated with disease
activity, suggesting that there is no important role for
70Kapop in the initiation of disease flares. However, it is pos-
sible that the variations in antibody levels against the apop-
tosis-specific epitope are masked by the presence of
antibodies against other epitopes on 70K and U1-70Kapop.
Furthermore, a polyspecific secondary antibody was used
to detect bound serum antibodies, and as a consequence
variations in isotype-specific antibody levels might have
remained undetected.
It has been reported that the first autoantibodies to appear
in anti-RNP-positive patients are generally antibodies
against 70K [16,27]. Our results suggest that 70Kapop
drives the primary autoimmune response to 70K, because
in several patients antibodies against an epitope associ-
ated with 70Kapop preceded the appearance of reactivity
with intact 70K. The fact that the first serum samples from
relatively few patients exclusively contain anti-70Kapop anti-
bodies might be due to the stage of disease development
at which the patient enters the rheumatological clinic. It is
likely that the first symptoms, later followed by the diagno-
sis of the disease, had been established years before the
start of the longitudinal study. Moreover, it is possible that
autoantibodies, especially those generated by the primary
immune response, were already present before the mani-
festation of clinical symptoms and that subsequent epitope
spreading might have occurred before the patient entered
the rheumatological clinic. For example, anti-cyclic citrulli-
nated peptide autoantibody is a very specific marker for
rheumatoid arthritis, and such antibodies can be detected
in patients up to 10 years before the occurrence of the first
clinical symptoms [28,29]. In our opinion this might explain
why a relative enrichment of anti-70Kapop antibodies could
not be detected in the early sera of all patients.
During apoptosis, the U1 snRNP complex is modified in
several ways. In addition to cleavage of 70K, U1 snRNA
and the Sm-F protein are cleaved, and phosphorylated ser-
ine–arginine proteins associate with the complex [30].
Apoptotic modifications of the U1A and U1C proteins have
not yet been described. 70K can be cleaved by caspase-3
and granzyme B, and it can be oxidatively fragmented in the
presence of metals, resulting in products of 40, 60 and 55
kDa, respectively. Correlations between the recognition of
specific 70K fragments and disease manifestations are
interesting. For example, patients suffering from Raynaud's
phenomenon preferentially recognize the oxidatively modi-
fied 55 kDa fragment of 70K [31]. The findings that early
MCTD sera are enriched for antibodies against the 40 kDa
apoptotic fragment (70Kapop) and that most sera show a
higher reactivity with this fragment suggest that caspase-3
cleaved 70K has a role in breaking tolerance in these
patients. Although granzyme B is postulated to have a role
in breaking tolerance [32] to 70K, it is unknown whether
specific patient groups preferentially recognize the 60 kDa
cleavage product generated by granzyme B, which would
be interesting to study in more detail.
Conclusions
Analysis of a group of MCTD patient sera by western blot-
ting showed that the majority of patient sera recognized
70Kapop more efficiently than the intact form of the 70K
protein. The fact that the presence of these antibodies in
most patients precedes the occurrence of other anti-70K
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antibodies suggests that 70Kapop is particularly important
for the early detection of this disease in patients.
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